Clear Street Group Inc. Increases Holdings in Drugs Made In America Acquisition Corp. $DMAA

Clear Street Group Inc. lifted its position in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 55.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 325,973 shares of the company’s stock after purchasing an additional 116,407 shares during the period. Clear Street Group Inc. owned 1.12% of Drugs Made In America Acquisition worth $3,382,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Wolverine Asset Management LLC boosted its holdings in shares of Drugs Made In America Acquisition by 4.7% in the fourth quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock valued at $13,564,000 after purchasing an additional 58,340 shares during the period. Mercuria Capital Strategies LLC purchased a new stake in shares of Drugs Made In America Acquisition in the fourth quarter valued at approximately $7,511,000. Boothbay Fund Management LLC purchased a new stake in shares of Drugs Made In America Acquisition in the second quarter valued at approximately $5,814,000. Radcliffe Capital Management L.P. boosted its holdings in shares of Drugs Made In America Acquisition by 316.7% in the third quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock valued at $5,424,000 after purchasing an additional 401,378 shares during the period. Finally, Quarry LP boosted its holdings in shares of Drugs Made In America Acquisition by 1,595.5% in the fourth quarter. Quarry LP now owns 266,551 shares of the company’s stock valued at $2,765,000 after purchasing an additional 250,830 shares during the period.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Drugs Made In America Acquisition has a consensus rating of “Sell”.

Drugs Made In America Acquisition Price Performance

Shares of NASDAQ:DMAA opened at $10.61 on Friday. Drugs Made In America Acquisition Corp. has a 52 week low of $10.17 and a 52 week high of $10.62. The firm has a 50 day moving average of $10.57 and a 200 day moving average of $10.47.

Drugs Made In America Acquisition (NASDAQ:DMAA) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.06 EPS for the quarter.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.